Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term multicenter. Found 14 abstracts

Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study. Clinical Lymphoma Myeloma & Leukemia. 2012 Aug;12(4):238-43.   PMCID: *
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Hague S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m(2) for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1391-8.   PMCID: no NIH
LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012 Mar;119(9):2093-9.   PMCID: not NIH funded
Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opinion on Biological Therapy. 2012 Oct;12(10):1415-21.   PMCID: Not NIH Funded
Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 2012 Jul;134(2):751-7.
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Dec;10(12):1487-98.   PMCID: Not NIH fund
Murphy C, Anderson PR, Li TY, Bleicher RJ, Sigurdson ER, Goldstein LJ, Swaby R, Denlinger C, Dushkin H, Nicolaou N, Freedman GM. IMPACT OF THE RADIATION BOOST ON OUTCOMES AFTER BREAST-CONSERVING SURGERY AND RADIATION. International Journal of Radiation Oncology Biology Physics. 2011 Sep;81(1):69-76.   PMCID: PMC2992091
Mortimer JE, Barsevick AM, Bennett CL, Berger AM, Cleeland C, DeVader SR, Escalante C, Gilreath J, Hurria A, Mendoza TR, Rugo HS. Studying Cancer-Related Fatigue: Report of the NCCN Scientific Research Committee. Journal of the National Comprehensive Cancer Network. 2010 Dec;8(12):1331-9.   PMCID: not NIH funded
Arciero CA, Joseph N, Watson JC, Hoffman JP. Partial stomach-partitioning gastrojejunostomy for malignant duodenal obstruction. AMERICAN JOURNAL OF SURGERY. 2006 Mar;191(3):428-32.
Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ, Carter BA, Catelano E, Hendrickson MR, Hibshoosh H, Layfield LJ, Memeo L, Wu H, O'Malley FP. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Modern Pathology. 2006 Feb;19(2):195-207.
Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study. Journal of Clinical Oncology. 2005 Dec;23(34):8646-54.
Langer C, Lilenbaum R. Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer. Seminars in Oncology. 2004 Dec 11;31(6):8-15.
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. International Journal of Radiation Oncology Biology Physics. 2000 Aug;48(1):7-16.
Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology. 1999 Dec;17(12):3793-803.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term multicenter

multicenter carcinoma randomized-trial chemotherapy therapy progression-free survival cancer tamoxifen radiotherapy irradiation features phase-iii growth-factor receptor antigen stomach-partitioning gastrojejunostomy double-blind cisplatin immunochemotherapy phase-ii trial supraglottic carcinoma pathology trial antibody cetuximab fatigue assessment 10-deazaaminopterin transplantation quality-of-life platinum-based anti-b1 radioimmunotherapy advanced colorectal-cancer elderly-patients gastroenterostomy carcinomas assay c225 patients recurrent metaanalysis european mcl network idec-c2b8 regimens treatable contributing squamous-cell carcinoma pain surgical palliation surgical clips mutations locally advanced head methylphenidate gemcitabine factors to fatigue gene-expression antrectomy brca1 marrow transplantation consistency malignant obstruction doxorubicin accelerated fractionation t-cell lymphoma invasive breast cancer interobserver reproducibility-familial breast cancer-breast survival conventional radiotherapy pancreatic-cancer superior combination Radiation boost placebo-controlled trial phase-ii prospective Radiation therapy breast-cancer 2000 wble b-p189 Breast cancer prognosis irinotecan anti-cd20 monoclonal-antibody iii randomized-trial paclitaxel supportive care sgn-30 1987 arlson me-journal of chronic diseases-v40-p373 stem-cell transplantation gemcitabine plus depression medullary carcinoma expression plus cetuximab radiochemotherapy mantle-cell lymphoma dose-escalation colorectal-cancer variability follow-up tumor bed prophylactic gastrojejunostomy disease gastric outlet obstruction brentuximab vedotin antibody-drug conjugate-CD30-Hodgkin's lymphoma-MMAE-SGN-35 biweekly cetuximab diagnosis bendamustine oropharyngeal Surgery hematologic malignancies hyperfractionation chronic lymphocytic-leukemia wisconsin-oncology-network dexamethasone TOP2A RNA expression Breast cancer-Recurrence fractionation previously untreated ovarian cancer family registry Efficacy Antifolate-Relapsed-Refractory peripheral T-cell lymphoma-Safety-Transformed mycosis fungoides mipi head and neck cancer kappa clinical-trials toxicity targeted therapy unresectable periampullary cancer Cancer-related fatigue rituximab international prognostic index palliation i-131 topoisomerase-ii-alpha signature maintenance rituximab
Last updated on Friday, August 07, 2020